Medprin Regenerative Medical Technologies Co., Ltd. (301033.SZ) has officially announced that its research project involving the "absorbable hemostatic fluid gelatin" has recently entered the clinical trial phase.
The medical device is intended for use during surgical procedures as an adjunct to control bleeding when compression, ligation, electrocautery, or other conventional hemostatic methods are ineffective or impractical for managing hemorrhage from small arteries, veins, or capillaries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.